bioaccess® vs Dominican Republic

You picked the Dominican Republic. Our DR page covers institutional REC review on a timeline that varies by study (we confirm it per protocol) and CONABIOS-level review on a timeline that varies by study (we confirm it per protocol). DIGEMAPS is the named regulator. No new DR median is added, and there is no published Miami–DR flight-hour figure. Ask for a study-specific calendar. If you need country 2 — El Salvador, Panama, the Dominican Republic, Chile, Costa Rica, or another jurisdiction we already run — bioaccess® is the same First-in-Human CRO on that next file. First-patient timing varies by study (we confirm it per protocol) and ethics review timed to each committee's meeting schedule are the published LATAM positions. A public hop exists: Dominican Republic, then Australia, then Canada, then an FDA conversation. We describe the pattern. We do not name the sponsor.

Built for

Not the right fit if

Head-to-head: bioaccess® vs Dominican Republic

Metricbioaccess®Dominican Republic
Role in your planCountry 2 / the rescue or expansion path — the same First-in-Human CRO on the next LATAM fileCountry 1 — the Dominican Republic you already picked. Our CRO-in-DR page is /clinical-trials-dominican-republic
Start-up clockFirst-patient timing varies by study (we confirm it per protocol) and ethics review timed to each committee's meeting schedule on the wider LATAM list. Country-2 clocks are asked as a study-specific calendarPublished DR clocks: institutional REC (varies by study; we confirm per protocol); CONABIOS (varies by study; we confirm per protocol). No new DR median is added
RegulatorINVIMA, COFEPRIS, ANVISA, ANMAT, ISP, MINSA, DIGEMAPS and the other authorities on our country pages — matched to the second countryDIGEMAPS (Ministry of Public Health) and CONABIOS — on our DR pages. Those are the regulators
Per-patient / program costBudget depends on study design; we provide a study-specific quote.Covered on our DR page; no new figure here
EntityNone to stand up for the trial file. Contract and startbioaccess® does not claim a Dominican clinical-trial legal entity. Our market-access page states a Dominican entity for the Authorized Representative / registration-holder role — that is a second file
FDA acceptance & data applicabilityData conducted under GCP (ISO 14155 for devices; ICH E6 for drugs) is eligible for FDA submission and review under 21 CFR 812.28 or 312.120. Eligibility is not clearance or approvalOur DR page states the same 21 CFR 812.28 eligibility for Dominican Republic data when GCP, ethics, and consent are met
Distance & time zone from the U.S.Same or adjacent U.S. time zones; ~3–8 hour flights on the published LATAM compare (Australia page)Our DR page covers direct US flights and US East Coast time-zone alignment. There is no published Miami–DR flight-hour figure
Where the hub is the better pageCountry 2 — El Salvador, Panama, the Dominican Republic, Chile, Costa Rica, or another jurisdiction we already runCRO in the Dominican Republic / CRO en República Dominicana — that category lives on /clinical-trials-dominican-republic

Comparison uses widely-known category facts about Dominican Republic and published US benchmark ranges — not Dominican Republic-specific figures. bioaccess® figures reflect our FIH-12™ operating model.

Why bioaccess® for first-in-human

You picked the Dominican Republic. Our CRO-in-DR page covers that category: Miami headquarters, DIGEMAPS, CONABIOS, REC (varies by study; we confirm per protocol), CONABIOS (varies by study; we confirm per protocol). If you only need the Dominican Republic file, start there.

This comparison covers country 2. Another Latin American jurisdiction after a DR first-in-human, or a hop out of region. bioaccess® is the same First-in-Human CRO on that next file. bioaccess® does not claim a Dominican clinical-trial legal entity. There is no published Miami–DR flight-hour figure. Direct US flights and US East Coast time-zone alignment are on our DR page.

A public hop exists: Dominican Republic, then Australia, then Canada, then an FDA conversation. We describe the pattern. We do not name the sponsor, the device, or commercial terms. bioaccess® is built for the Latin American legs of a hop like that.

Foreign device data is eligible for FDA submission and review under 21 CFR 812.28 when GCP / ISO 14155, ethics, and consent are met. Eligibility is not clearance or approval. Ask for a study-specific calendar. No new DR median is added.

Frequently asked questions

Is this the CRO-in-Dominican-Republic page?

No. Our CRO-in-DR page, /clinical-trials-dominican-republic, covers CRO in the Dominican Republic / CRO en República Dominicana, DIGEMAPS, CONABIOS, and the REC and CONABIOS review steps (timing varies by study; we confirm per protocol). This comparison covers country 2 after a DR first-in-human.

How long does ethics take in the Dominican Republic?

Our DR page covers institutional REC review on a timeline that varies by study (we confirm it per protocol) and CONABIOS-level review on a timeline that varies by study (we confirm it per protocol). No new median is added. Ask for a study-specific calendar.

How long is the flight from Miami to the Dominican Republic?

There is no published Miami–DR flight-hour figure. Our DR page covers direct US flights and US East Coast time-zone alignment.

What is the Dominican Republic → Australia → Canada → FDA pattern?

A public multi-country hop exists: a first-in-human start in the Dominican Republic, then Australia, then Canada, then an FDA conversation. We describe the pattern. We do not name the sponsor, the device, or commercial terms. bioaccess® is built for the Latin American legs of a hop like that.

You might prefer the DR hub if…

You only need the CRO-in-Dominican-Republic category — DIGEMAPS, CONABIOS, sites named on that page, and the published clocks. Go to /clinical-trials-dominican-republic. Use this comparison when country 1 is the Dominican Republic and you need country 2.

All CRO comparisons · First-in-Human CRO · Clinical Trials in Panama · Book a free 30-min strategy call